Indomethacin nanocrystals prepared by different laboratory scale methods: effect on crystalline form and dissolution behavior
Source abstract
Abstract
The objective of this study is to select very simple and well-known laboratory scale methods able to reduce particle size of indomethacin until the nanometric scale. The effect on the crystalline form and the dissolution behavior of the different samples was deliberately evaluated in absence of any surfactants as stabilizers. Nanocrystals of indomethacin (native crystals are in the γ form) (IDM) were obtained by three laboratory scale methods: A (Batch A: crystallization by solvent evaporation in a nano-spray dryer), B (Batch B-15 and B-30: wet milling and lyophilization), and C (Batch C-20-N and C-40-N: Cryo-milling in the presence of liquid nitrogen). Nanocrystals obtained by the method A (Batch A) crystallized into a mixture of α and γ polymorphic forms. IDM obtained by the two other methods remained in the γ form and a different attitude to the crystallinity decrease were observed, with a more considerable decrease in crystalline degree for IDM milled for 40 min in the presence of liquid nitrogen. The intrinsic dissolution rate (IDR) revealed a higher dissolution rate for Batches A and C-40-N, due to the higher IDR of α form than γ form for the Batch A, and the lower crystallinity degree for both the Batches A and C-40-N. These factors, as well as the decrease in particle size, influenced the IDM dissolution rate from the particle samples. Modifications in the solid physical state that may occur using different particle size reduction treatments have to be taken into consideration during the scale up and industrial development of new solid dosage forms.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems · Crystallography and molecular interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Ali HSM, York P, Blagden N (2009) Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 375:107–11310.1016/j.ijpharm.2009.03.029 ↗
2. Allen DJ, Kwan KC (1969) Determination of degree of crystallinity in solid–solid equilibria. J Pharm Sci 58:1190–119310.1002/jps.2600581004 ↗
3. Banakar UV (1992) Pharmaceutical dissolution testing. In: Swarbrick J (ed) Pharmaceutical dissolution testing. Marcel Dekker, New York, pp 55–105
4. Borka L (1974) The polymorphism of indomethacin. Acta Pharm Suec 11:295–303
5. Chan H-K, Kwok PCL (2011) Production methods for nanodrug particles using bottom-up approach. Adv Drug Del Rev 63:406–41610.1016/j.addr.2011.03.011 ↗
6. Chen H, Khemtong C, Yang X, Chang X, Gao J (2011) Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 16:354–36010.1016/j.drudis.2010.02.009 ↗
7. Crowley KJ, Zografi G (2002) Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91:492–50710.1002/jps.10028 ↗
8. Gao L, Zhang D, Chen M (2008) Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845–86210.1007/s11051-008-9357-4 ↗
9. Gashi Z, Censi R, Malaj L, Gobetto R, Mozzicafreddo M, Angeletti M, Masic A, Di Martino P (2009) Differences in the interactions between different aryl propionic acid derivatives and poly(vinylpyrrolidone) K30:a multi-methodological approach. J Pharm Sci 98:4216–422810.1002/jps.21734 ↗
10. Ghosh I, Bose S, Vippagunta R, Harmon F (2011) Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 409:260–26810.1016/j.ijpharm.2011.02.051 ↗
11. Grant DJW (1999) Theory and origin of polymorphism. In: Brittain HG (ed) Polymorphism in pharmaceutical solids. Marcel Dekker, New York, pp 227–278
12. Jimbo G (1986) Recent formulation technologies and their application 3. Iyaku, Journal Inc, Tokyo, pp 168–172
13. Junghanns JHAH, Müller RH (2008) Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 3:295–309
14. Kaneniwa N, Otzuka M, Hayashi T (1985) Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. Chem Pharm Bull 33:3447–345510.1248/cpb.33.3447 ↗
15. Keck MC, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 62:3–1610.1016/j.ejpb.2005.05.009 ↗
16. Laaksonen T, Liu P, Rahikkala A, Peltonen L, Kauppinen EI, Hirvonen J, Järvinen K, Raula J (2011) Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods. Pharm Res 28:2403–241110.1007/s11095-011-0456-z ↗
17. Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadd AM (2009) Diclofenac nanosuspensions influence of preparation procedure and crystal form on drug dissolution behavior. Int J Pharm 373:124–13210.1016/j.ijpharm.2009.01.024 ↗
18. Legendre B, Feutelais Y (2004) Polymorphic and thermodynamic study of indomethacin. J Therm Anal Calorim 76:255–26410.1023/B:JTAN.0000027824.55280.37 ↗
19. Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U (2007) Amorphous drug nanosuspensions. Particle dissolution and crystal growth. Langmuir 23:9866–987410.1021/la700811b ↗
20. Liu P, Rong X, Laru J, Van Veen B, Kiesvaara J, Hirvonen J, Laaksonen T, Peltonen L (2011) Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm 411:215–22210.1016/j.ijpharm.2011.03.050 ↗
21. Martena V, Censi R, Hoti E, Malaj L, Di Martino P (2012) A new nano spray drying method for the preparation of nicergoline pure nanoparticles. J Nanopart Res 14:93410.1007/s11051-012-0934-1 ↗
22. Monkhouse DC, Lach JL (1972) Use of adsorbents in enhancement of drug dissolution. J Pharm Sci 61:1435–144110.1002/jps.2600610918 ↗
23. Mullin JW (1993) Crystallization, 3rd edn. Butterworth-Heinemann, Oxford
24. Niwa T, Nakanishi Y, Danjo K (2010) One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen. Eur J Pharm Sci 41:78–8510.1016/j.ejps.2010.05.019 ↗
25. Nováková L, Matysová L, Havlíková L, Solich P (2005) Development and validation of HPLC method for determination of indomethacin and its two degradation products in topical gel. J Pharm Biomed Anal 37:899–90510.1016/j.jpba.2004.09.012 ↗
26. Noyes A, Whitney WR (1897) The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930–93410.1021/ja02086a003 ↗
27. Otsuka M, Kaneniwa N (1988) A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 36:4026–403210.1248/cpb.36.4026 ↗
28. Shegokar R, Müller RH (2010) Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 399:129–13910.1016/j.ijpharm.2010.07.044 ↗
29. Verma S, Kumar S, Gokhale R, Burgess DJ (2011) Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm 406:145–15210.1016/j.ijpharm.2010.12.027 ↗
30. Wu L, Zhang J, Watanabe W (2011) Physical and chemical stability of drug nanoparticles. Adv Drug Del Rev 63:456–46910.1016/j.addr.2011.02.001 ↗
31. Yamamoto H (1968) 1-Acyl-indoles. II. A new syntheses of 1-(ion-chlorobenzoyl)-5-methoxy-3-indolacetic acid and its polymorphism. Chem Pharm Bull 16:17–1910.1248/cpb.16.17 ↗
32. Zhang X, Xia Q, Gu N (2006) Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm 32:857–86310.1080/03639040500534184 ↗